Table 2.

Efficacy outcomes of cabozantinib in patients with mRCC according to PPI use

Efficacy outcomes	PPI users, n = 43 (43.4%)	PPI nonusers, n = 56 (56.6%)	p value
Overall response rate, n (%)	14 (33.4)	21 (38.2)	.674
Disease control rate, n (%)	40 (95.2)	49 (89.1)	.464
Median PFS, (95% CI) mo	9.6 (95% CI, 8.6–10.6)	9.1 (95% CI, 7.5–10.7)	.402
HR (95% CI)	0.837 (0.551–1.273)	0.837 (0.551–1.273)
Median OS, (95% CI) mo	17.2 (95% CI, 13.9–20.5)	22.8 (95% CI, 17.0–28.6)	.138
HR (95% CI)	1.441 (0.886–2.342)	1.441 (0.886–2.342)

Abbreviations: CI, confidence interval; HR, hazard ratio; mRCC, metastatic renal cell carcinoma; OS, overall survival, PFS, progression‐free survival; PPI, proton pump inhibitor; TTF, time‐to‐treatment failure.